Navigating Shareholder Litigation Risk in the Life Sciences Sector
Risk & Insurance - Mar 02, 2026
From clinical trial readouts to regulatory uncertainty, life science companies face unique D&O exposures at every stage of development — but disciplined practices and specialized insurance support can help mitigate the risk. The post Navigating Shareholder Litigation Risk in the Life Sciences S...
Recommended Articles
Posted: Mar 05, 2026
Premium expansion moderates to 9.7% through Q3 2025, while fronting companies and new market entrant...
Posted: Mar 05, 2026
A global survey of business leaders exposes a widening gap between supply chain risk awareness and f...
Posted: Mar 05, 2026
The latest people news in the industry today. The post Gareth Davies Appointed Executive Vice Presid...